Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product, Procedure, and Disease Indication : Global Opportunity Analysis and Industry Forecast, 2021–2028

Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product, Procedure, and Disease Indication : Global Opportunity Analysis and Industry Forecast, 2021–2028

  • June 2021 •
  • 266 pages •
  • Report ID: 6126663 •
  • Format: PDF
Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product (Endoscope, Mechanical Endoscopic Equipment, Visualization and Documentation Systems, Accessories, and Other Endoscopy Equipment), Procedure (Gastric Balloon, Aspiration Therapy, Endoscopic Sleeve Gastroplasty, Gastric Injection, and Lap Band Surgery), and Disease Indication (Obesity, Type II Diabetes, and Nonalcoholic Steatohepatitis [NASH]): Global Opportunity Analysis and Industry Forecast, 2021–2028

The global endoscopy devices for obesity, type II diabetes and NASH market was valued at $2,638.99 million in 2019, and is projected to reach $3,711.43 million by 2027, registering a CAGR of 7.6% from 2021 to 2028. Endoscopy devices are the medical devices with light attached to look inside the body cavity or organ by inserting through a natural opening such as the mouth or through incisions. An endoscopy is the minimally invasive medical procedure that diagnoses, prevents, and treats complications associated with visceral organs. Endoscopic devices consist of flexible tubing that contains a series of lighted mirror lenses and optic fibers. These devices are used in the diagnosis of gastrointestinal tract, small intestine, large intestine/colon, bile duct, rectum, respiratory tract, ear, urinary tract, and female reproductive systems. The market mainly focuses on the endoscopic devices used in the endoscopic surgeries used in treating diseases such as obesity, type II diabetes, and non-alcoholic steatohepatitis.

Surge in obese population, technological advancements, rise in prevalence rate of diseases that require endoscopy devices, growth in patient preference for minimally invasive surgeries, favorable FDA approvals, and reimbursement policies in developed economies, shorter recovery time and minimal postoperative complications are the key factors that fuel the growth of the endoscopy devices for obesity, type II diabetes and NASH market. Furthermore, rise in prevalence of diabetes within the population is expected to supplement the market growth throughout the analysis period. For instance, according to the data published by National Institute of Health (NIH), in 2017, approximately 462 million individuals were affected by type II diabetes, corresponding to 6.28% of the world’s population. Moreover, increase in the geriatric population vulnerable to obesity and comorbid conditions related to obesity, which necessitates the use of endoscopic procedures for diagnosis & treatment is anticipated to boost the market growth in near future. However, dearth of trained physicians & endoscopists and infections associated with the use of endoscopes are expected to hinder the growth of the market.

The global endoscopy devices for obesity, type II diabetes and NASH market is segmented into product type, procedure, disease indication, and region. By product type, the market is categorized into endoscope, mechanical endoscopic equipment, visualization & documentation systems, accessories, and other endoscopy equipment. By procedure, the market is segmented into gastric balloon, aspiration therapy, endoscopic sleeve gastroplasty, gastric injection, and lap band surgery. On the basis of disease indication, the endoscopy devices for obesity, type II diabetes and NASH market is classified into obesity, type II diabetes and nonalcoholic steatohepatitis (NASH). Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
? An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
? A comprehensive analysis of the factors that drive and restrain the growth of the global endoscopy devices for obesity, type II diabetes and NASH market is provided.
? An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS
• By Product
o Endoscope
o Mechanical endoscopic equipment
o Visualization and documentation systems
o Accessories
o Other endoscopy equipment
• By Procedure
o Gastric balloon
o Aspiration therapy
o Endoscopic sleeve gastroplasty
o Gastric injection
o Lap band surgery
• By Disease indication
o Obesity
o Type II Diabetes
o Nonalcoholic Steatohepatitis (NASH
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

KEY MARKET PLAYERS
• Apollo Endosurgery Inc.
• Aspire Bariatrics Inc.
• Endo Tools Therapeutics S.A
• Fractyl Laboratories Inc.
• GI Dynamics Inc.
• GI Windows Inc.
• Medtronic plc
• Obalon Therapeutics Inc.
• ReShape Lifesciences Inc.
• Spatz FGIA Inc.
• USGI Medical Inc.